EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Corbus Pharmaceuticals Holding (CRBP) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Corbus Pharmaceuticals Holding $6.43, price $7.45, upside -13.7%, quality 13 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US21833P3010

CP Corbus Pharmaceuticals Holding logo Thin data Sep 24, 2026

Corbus Pharmaceuticals Holding

CRBP · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $6.43 · Overvalued (−14%)
!Quality 13/100
!Weak Growth (revenue 5y −14.3 %/yr)
!Low debt · negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 15 out of 100
Watch Corbus Pharmaceuticals Holding for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$62.10 $2.14 Fair Value $6.43 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $2.14 – $62.10 · fair‑value band $4.24 – $8.03 · the $7.45 price screens above the $6.43 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Corbus Pharmaceuticals in your weekly email

Every Wednesday you see whether Corbus Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.

Show more

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Stock analysis

Corbus Pharmaceuticals Holding (CRBP) currently trades at $7.45, while our model-based Fair Value estimate is $6.43, implying the stock looks roughly 15.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $4.24 (bear) to $8.03 (bull), the price of $7.45 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 13/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Corbus Pharmaceuticals Holding reported revenue of $0 in FY2025 versus $882K in FY2021. Reported net income was −$78.5M in FY2025.

Key figures

Market cap $156M · EPS (TTM) $−6.11 · Return on equity −95.6% · Return on assets (EBIT) −69.2% · Free cash flow −$64.5M · Net cash $26.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −14%, CRBP screens richer than that median.

Fair Value models

Bear $4.24 Fair Value $6.43 Bull $8.03
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.81 $5.11 $7.63 54
All 1 models by family
Asset-Based
NCAV (Graham) $3.81 $5.11 $7.63 54

Open the full fair value analysis →

Notify me when CRBP reaches fair value

Put CRBP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 13/100

Of which business quality 20 · Market factors (momentum, volatility) 15

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 21
Earnings quality: real cash, not paper profit
Fin. Strength 61
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−77.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.3%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,045.6% (2016) → −6,350.1% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRBP screens 16% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Corbus Pharmaceuticals Holding with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside −14% · Above median
Profitability
Return on assets −53% · Bottom 25%
Operating margin (TTM) 0% · Above median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.06× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Corbus Pharmaceuticals Holding · Fair Value
$6.43 −16%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Corbus Pharmaceuticals Holding Fair Value". https://www.fairvalue-calculator.com/stock/CRBP

Frequently asked questions

Is Corbus Pharmaceuticals Holding (CRBP) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $6.43 versus a price of $7.45, about −14% upside (overvalued).
What is the fair value of CRBP?
Our model-based fair value for Corbus Pharmaceuticals Holding is $6.43 (as of Sep 24, 2026), built from audited fundamentals. The current price: $7.45.
What is the quality score of CRBP?
Corbus Pharmaceuticals Holding has a Quality Score of 13/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corbus Pharmaceuticals Holding (CRBP)?
Our model-based price target is the fair value of $6.43 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $4.24, optimistic scenario $8.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Corbus Pharmaceuticals Holding stock forecast for 2026?
Our models put fair value at $6.43, about −14% upside versus a price of $7.45 (overvalued). Cautious scenario $4.24, optimistic scenario $8.03. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Corbus Pharmaceuticals Holding (CRBP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corbus Pharmaceuticals Holding it is $6.43 per share (as of Sep 24, 2026), against a price of $7.45. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Corbus Pharmaceuticals Holding stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CRBP trades above its calculated fair value: price $7.45, fair value $6.43, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRBP?
No. The price is what the market pays today ($7.45); the fair value is what the company's own numbers justify ($6.43). For Corbus Pharmaceuticals Holding the two are $1.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Corbus Pharmaceuticals Holding worth?
The market values Corbus Pharmaceuticals Holding at about $156M (market capitalisation, as of Sep 24, 2026). Per share that is $7.45; our models calculate a fair value of $6.43 per share.
What do the bullish and bearish scenarios say about CRBP?
Our models span a range for Corbus Pharmaceuticals Holding: cautious scenario $4.24, base $6.43, optimistic $8.03 per share (as of Sep 24, 2026, price $7.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Corbus Pharmaceuticals Holding (CRBP)?
Balance-sheet figures for Corbus Pharmaceuticals Holding (as of Sep 24, 2026): return on equity −95.6%, debt of 0.11 per unit of equity. They feed the Quality Score of 13/100, which measures business quality independently of the share price.
How far is CRBP from its 52-week high?
Corbus Pharmaceuticals Holding trades at $7.45, about 62% below its 52-week high of $19.36 and 8% above the low of $6.92 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $6.43 is for.
Which stocks are comparable to Corbus Pharmaceuticals Holding?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corbus Pharmaceuticals Holding stock attractive at the current price?
The data as of Sep 24, 2026: price $7.45, calculated fair value $6.43 (−14%), Quality Score 13/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRBP calculated?
We run Corbus Pharmaceuticals Holding through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.43, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Corbus Pharmaceuticals Holding itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corbus Pharmaceuticals Holding (CRBP)?
The closing price on Sep 24, 2026 was $7.45. Our model-based fair value is $6.43, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corbus Pharmaceuticals Holding right now?
A fairly wide model range ($4.24 to $8.03) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Corbus Pharmaceuticals Holding

How large is the market capitalisation of Corbus Pharmaceuticals Holding (CRBP)?
The market capitalisation of Corbus Pharmaceuticals Holding is $156M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Corbus Pharmaceuticals Holding (CRBP)?
Earnings per share at Corbus Pharmaceuticals Holding are $−6.11. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Corbus Pharmaceuticals Holding (CRBP)?
The return on equity (ROE) of Corbus Pharmaceuticals Holding is −95.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corbus Pharmaceuticals Holding (CRBP)?
On an EBIT basis the return on assets of Corbus Pharmaceuticals Holding is −69.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Corbus Pharmaceuticals Holding (CRBP) generate?
The free cash flow of Corbus Pharmaceuticals Holding is −$64.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Corbus Pharmaceuticals Holding (CRBP) hold?
Corbus Pharmaceuticals Holding holds more cash than debt, $26.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Corbus Pharmaceuticals Holding in the live analysis

One click puts Corbus Pharmaceuticals Holding on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.